Community Health Advocates for Motivating PAP Use in Our Neighborhoods.

NCT ID: NCT06047353

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-29

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to compare the impact of motivational enhancement therapy (MET), delivered by culturally congruent community health care workers (CHWs) versus usual care patients with previously untreated moderate-to-severe obstructive sleep apnea (OSA) on adherence to positive airway pressure (PAP) therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Motivational Enhancement Therapy (MET)

Participants in this group will receive intervention with MET along with PAP therapy. Participants will be in this group for approximately 3 months.

Group Type EXPERIMENTAL

Motivational Enhancement Therapy

Intervention Type BEHAVIORAL

Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize behavioral change. MET will be given via phone and/or in person (approximately 30 minutes) at baseline, week 1, week 2, week 4, and week 8.

Positive Airway Pressure (PAP) therapy

Intervention Type DEVICE

Positive Airway Pressure (PAP) therapy will be administered as per standard of care.

PAP therapy

Participants in this group will receive PAP therapy which is the standard of care. Participants will be in this group for approximately 3 months.

Group Type ACTIVE_COMPARATOR

Positive Airway Pressure (PAP) therapy

Intervention Type DEVICE

Positive Airway Pressure (PAP) therapy will be administered as per standard of care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Motivational Enhancement Therapy

Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize behavioral change. MET will be given via phone and/or in person (approximately 30 minutes) at baseline, week 1, week 2, week 4, and week 8.

Intervention Type BEHAVIORAL

Positive Airway Pressure (PAP) therapy

Positive Airway Pressure (PAP) therapy will be administered as per standard of care.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years of age
* Moderate-to-severe OSA
* Available to attend study visits and sessions
* Reliable access to a phone

Exclusion Criteria

* Prior or current use of PAP therapy or other treatment (e.g., oral appliance) for OSA
* History of upper airway surgery for OSA
* Moderate to severe insomnia
* Commercial drivers
* Use of non-standard PAP including adaptive servo-ventilation or bi-level positive airway pressure
* Report of motor vehicle accident or near-miss due to sleepiness within the 2 previous years
* Unstable medical conditions that may preclude enrollment in the protocol such as: uncontrolled angina and/or congestive heart failure, uncontrolled blood pressure or resistant hypertension, severe chronic obstructive pulmonary disease, cancer, and active psychiatric disease (e.g., major depression)
* Other sleep disorders (e.g., circadian rhythm disorder)
* Use of supplemental oxygen during wakefulness or sleep
* Central sleep apnea, obesity hypoventilation syndrome or Cheyne-Stokes respiration based on the home sleep apnea test
* Resting awake oxygen saturation (SpO2) \< 90%
* Participation in another clinical trial
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

Sponsor Role collaborator

University of Miami

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Naresh Punjabi

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Naresh Punjabi

Role: PRINCIPAL_INVESTIGATOR

University of Miami

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Miami

Miami, Florida, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Naresh Punjabi, MD

Role: CONTACT

Phone: 305-243-6388

Email: [email protected]

Naresh Punjabi

Role: CONTACT

Phone: 3052436388

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Naresh M Punjabi, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20211138

Identifier Type: -

Identifier Source: org_study_id

P50MD017347

Identifier Type: NIH

Identifier Source: secondary_id

View Link